This transcript has been edited for clarity. Kenneth Pienta, MD: Hi. I am Dr. Ken Pienta, and I'm joined by my nurse practitioner colleague, Diane Reyes-Dagher, for this CareCues conversation on how ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer. The first patient has been dosed in a phase 1/2 trial ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A recent study found that AI can identify patients who will ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track ...

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...